Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Gp100-specific T lymphocyte therapy (Primary) ; MART-1-specific T lymphocyte therapy (Primary) ; Aldesleukin; Cyclophosphamide; Filgrastim; Fludarabine; Freund's adjuvant; Melanoma vaccine; Melanoma vaccine gp100; Montanide ISA-51
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 28 Oct 2015 Biomarkers information updated
- 23 Jul 2011 NCT00814684 states that the trial end date is Oct 2011.
- 23 Jul 2011 NCT00814684 states that the trial end date is Oct 2011.